Efficacy of Navitoclax and Ruxolitinib | Naveen Pemmaraju, MD | EHA 2024

Efficacy of Navitoclax and Ruxolitinib | Naveen Pemmaraju, MD | EHA 2024
Discussing the Unmet Clinical Needs in 2 Special CLL Patient Groups | Silvia Deaglio, MD | EHA 2024
Elranatamab (ELEREXFIO) Trial Updates | Bryan Husbeck | EHA 2024
EHA 2024: Can Patients Over 75 Be Treated with CAR T-cell Therapy?
